Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease char-
| INTRODUCTION
Amyotrophic lateral sclerosis (ALS; ORPHA803), also known as "Lou Gehrig's disease", is a clinically heterogeneous group of neurodegenerative disorders characterized by the death of motor neurons in the brain, brainstem, and spinal cord resulting in fatal paralysis (Morrison & Harding, 1994) . Approximately, 90% of ALS cases are sporadic and the remaining 10% are familial (Valdmanis & Rouleau, 2008) . The lifetime risk for developing the disease is approximately 1/400 (Johnston et al., 2006) . Due to the complex genetic background of the disease, the underlying disease-causing variant is rarely established for individual cases (Kenna et al., 2013) . To date, 126 genes have been implicated in ALS (Abel, Powell, Andersen, & Al-Chalabi, 2012) .
The most common mutants identified for the Mendelian forms are located in the superoxide dismutase 1 (SOD1) gene, which accounts for approximately 5% of the ALS forms (Andersen et al., 2007) . Mutations in the senataxin (SETX) gene have been identified at a lower frequency than in the SOD1 gene in ALS. SETX encodes a helicase protein involved in DNA repair and RNA production. Homozygous or compound heterozygous SETX mutations are associated with the development of autosomal recessive ataxia with oculomotor apraxia type 2 (AOA2; Anheim et al., 2009 ). In addition, heterozygous SETX mutations have been associated with the autosomal dominant form of juvenile-onset ALS (ALS4; Chen et al., 2004) . The fused in sarcoma (FUS) (Pearson et al., 2011) . A heterozygous hexanucleotide (GGGGCC) repeat expansion located between the noncoding exons 1a and 1b of C9ORF72 has been recently identified in patients with FTD and/or ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011) .
Considering the onset, the symptoms, and the course of the disease, our aim was to establish the frequencies of mutations in the coding regions of the SETX, FUS, and C9ORF72 genes in Hungarian patients (n = 28) that did not carry mutations in the SOD1 gene. The investigated patients were also negative for the C9ORF72 hexanucleotide repeat expansion.
| PATIENTS AND METHODS

| Investigated individuals
The investigated patients (n = 28) participated in this study were recruited from the Department of Neurology, University of Szeged, Szeged, Hungary. All patients fulfilled the revised El Escorial and the Awaji-shima criteria for ALS (de Carvalho & Swash, 2009; Ludolph et al., 2015) . According to the revised El Escorial criteria, the lower motor neuron disease (MND; progressive muscular atrophy) is determined as one of the "restricted phenotypes" of ALS; therefore, one patient with only lower motor neuron involvement was also diagnosed as ALS. All patients and age-and sex-matched healthy controls (n = 50) were of Hungarian ancestry. The investigation was approved by the Internal Ethical Review Board of the University of Szeged. Written informed consent was obtained from patients and healthy controls, and the study was conducted according to the Principles of the Declaration of Helsinki.
| Next-generation sequencing
Genomic DNA was isolated from blood using the DNeasy Blood and 
| Bioinformatic analysis
To improve the efficiency of the Roche pipeline, composed of the Roche 454 GS Reference Mapper for mapping (on UCSC human reference genome hg19) and Amplicon Variant Analyzer (v2.5p1) for variant calling, an additional in-house pipeline was used. 
| RESULTS
Our next-generation sequencing approach did not detect mutations in the investigated coding regions of the FUS and C9ORF72 genes.
We identified a novel heterozygous missense mutation (c. Further studies are needed to elucidate the underlying mechanism responsible for the observed unusual phenotypes associated with the heterozygous p.N264S and p.T1118I missense mutations of the SETX gene ( Table 1) .
The 17 known heterozygous missense mutations of the SETX gene are located in exons 1, 5, 8, 11, 12, 13, 17, and 24 (Table 2) .
Four of the 17 mutations are located within the helicase domain of the SETX protein (Chen et al., 2004; Hirano et al., 2011; Kenna et al., 2013; Saracchi et al., 2014) . In AOA2, homozygous or compound heterozygous missense mutations located within the helicase domain are generally associated with less severe phenotypes than the mutations affecting other regions of the protein (Anheim et al., 2009; Moreira et al., 2004 Zhao et al. (2009) this region can lead to the development of either spinal or bulbar motor neuron involvement (Table 2) .
It has also been demonstrated that, in AOA2, missense mutations affecting the N-terminal or the helicase domain of SETX cause phenotypes similar to those caused by deletions, nonsense, or frameshift mutations (Chen et al., 2006) . However, only missense SETX mutations have been implicated in the development of ALS4, to date (Avemaria et al., 2011; Hirano et al., 2011; Kenna et al., 2013; Saracchi et al., 2014) ; deletions, nonsense, frameshift, or other types of mutations
have not yet been detected for this disease (Table 2) .
Our study further widens the geographic range for the origin of disease-causing heterozygous missense mutations of the SETX gene, which have already been implicated in ALS in patients from different countries (Avemaria et al., 2011; Hirano et al., 2011; Kenna et al., 2013; Saracchi et al., 2014) . To the best of our knowledge, our study is the first demonstrating a novel SETX mutation in the Hungarian ALS population (Table 2) .
In this study, we did not identify any mutations in the coding regions of the C9ORF72 gene. These results correlate well with the data reported in the literature; there are currently no reports of disease-causing mutation in the coding regions of the C9ORF72 gene (Kenna et al., 2013; Koppers et al., 2013) .
No mutations in FUS, another Mendelian gene associated with domains (Shang & Huang, 2016) . On the basis of our results, we hypothesize that FUS mutations in the Hungarian ALS population might be very rare. This hypothesis is supported by the literature, as FUS mutations have been reported to contribute to the development of the disease in approximately 0.5% of the patients (Kenna et al., 2013) .
On the basis of our results and the results of previous studies, we also emphasize that the genetic screening of the Mendelian ALSassociated genes might not elucidate the causative genetic variant in the majority of ALS cases (Cirulli et al., 2015; Kenna et al., 2013) . The genetic heterogeneity of ALS is extremely complex: rare mutations of Mendelian genes and common variants of non-Mendelian genes can also contribute to the development of the disease (Abel et al., 2012) . Our comprehensive study adds novel data to the genetic and phenotypic diversity of ALS and indicates that complex approaches, high-throughput methods, and large-scale studies are needed to understand of the genetic heterogeneity of this disease.
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